Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04132102
Recruitment Status : Recruiting
First Posted : October 18, 2019
Last Update Posted : October 29, 2019
Sponsor:
Information provided by (Responsible Party):
Lu Shun, Shanghai Chest Hospital

Brief Summary:
This is an open-label, sing-arm, single site, phase IV clinical study. The main objective is to evaluate the efficacy of afatinib in LSQC patients with EGFR sensitive mutation, and to explore the clinical factors which might be predictive for the effectiveness in LSQC.

Condition or disease Intervention/treatment Phase
Lung Squamous Cell Carcinoma Drug: Afatinib Phase 4

Detailed Description:

This is an open-label, sing-arm phase IV clinical study which will recruit about 20 patients in China.

The main objective of this study is to evaluate the efficacy of afatinib in LSQC patients with EGFR sensitive mutation, and to explore the clinical factors which might be predictive for the effectiveness in LSQC.

Target patient population:Locally advanced (IIIB) or metastatic (stage IV) immunohistochemistry (IHC)-verified Lung squamous cell carcinoma (LSQC) with EGFR sensitive mutation patients, whom previously untreated or received platinum-based doublet chemotherapy as first-line treatment with subsequent disease progression, and had to be eligible for second-line treatment.

Investigational product, the dose and administration method: Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1 (CTCAE 5.0).

Study assessment: The collected data include the patient's demographic characteristics, information needed to determine whether the patient is eligible (including medical history, attributes of previous and current disease, and EGFR mutation status in tumor tissues), efficacy of objective response rate(ORR), progression-free survival (PFS), overall survival (OS), and safety (including serious adverse events and dose change-induced adverse events).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
Actual Study Start Date : November 27, 2018
Estimated Primary Completion Date : April 30, 2021
Estimated Study Completion Date : August 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Afatinib treatment group
This is an open-label, sing-arm phase IV clinical study
Drug: Afatinib
Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
Other Name: GIOTRIF®




Primary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: Up to 12 months ]
    PFS refers to the time from initial prescription of afatinib to the time of disease progression or death recorded in CRF in this study, no matter whether the patient withdraw from the treatment before disease progression or receive other anti-cancer treatment or not. For the patient without progression or death at the time of analysis, the latest assessment date will be used as interpolation (censoring). (Or, if there's no tumor assessment after baseline visit, baseline visit date will be used


Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Up to 12 months ]
    ORR refers to the incidence of complete remission (CR) or partial remission (PR) (determined according to RECIST1.1 standards)

  2. Overall survival (OS) [ Time Frame: Up to 12 months ]
    OS refers to the time from the patient entering into the group to the time of death. When it comes to the analysis of patients with unknown survival status, the last date when learning of the patient's survival will be used as interpolation (censoring)

  3. Rate of SAEs, dose change-induced AEs, and AEs of particular concerns. [ Time Frame: Up to 12 months ]
    Serious adverse events [SAEs], dose change-induced AEs, and AEs of particular concerns.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Selected patients must meet all of the following standards:

    1. The patient's or his/her legal representative's has signed and dated written informed consent before any specific study procedure.
    2. The patient is above 18 years old.
    3. Locally advanced (IIIB) or metastatic (stage IV) immunohistochemistry (IHC)-verified Lung squamous cell carcinoma (LSQC) with EGFR sensitive mutation patients, whom previously untreated or received platinum-based doublet chemotherapy as first-line treatment with subsequent disease progression, and had to be eligible for second-line treatment.
    4. The patient has NOT previously received EGFR-TKI treatment.
    5. ECOG Performance Status Score is 0~2.
    6. The patient has sufficient bone marrow and organ function proved by baseline complete plasma count, plasma biochemistry and urinary biochemistry tests.
    7. Female patients of childbearing age must use adequate contraceptives, and breastfeeding is not allowed.
    8. Male patients must voluntarily to use contraceptives.

      Exclusion criteria

  • Selected patients can not meet any one of the following standards:

    1. The patient has received EGFR-TKI treatment.
    2. The patient has any severe or uncontrolled systemic signs of illness, including uncontrolled hypertension, active easy-bleeding constitution, active infection, or significantly impaired function of bone marrow or organs, which researchers believe can significantly change the patient's risk/benefit balance.
    3. The patient has symptomatic central nervous system (CNS) metastases.
    4. The patient has the history of interstitial pneumonia, or radiation pneumonia which needs steroid treatment.
    5. The patient still has unrecovered toxic reaction with ≥ grade 3 (CTCAE5.0) caused by previously received treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04132102


Contacts
Layout table for location contacts
Contact: Yongfeng Yu, Master 18017321559 yuyongfeng212@126.com

Locations
Layout table for location information
China, Shanghai
Shanghai Chest Hospital Recruiting
Shanghai, Shanghai, China, 200030
Contact: Yongfeng Yu, Master         
Sponsors and Collaborators
Shanghai Chest Hospital
Investigators
Layout table for investigator information
Study Director: Yongfeng Yu, Master Shanghai Chest Hospital

Layout table for additonal information
Responsible Party: Lu Shun, Chief physician, Shanghai Chest Hospital
ClinicalTrials.gov Identifier: NCT04132102     History of Changes
Other Study ID Numbers: XK-LS-001
First Posted: October 18, 2019    Key Record Dates
Last Update Posted: October 29, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lu Shun, Shanghai Chest Hospital:
LSQC
EGFR mutation
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Afatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action